scout
|Videos|January 31, 2019

Combining BRAF, MEK and EGFR Inhibition in mCRC

Experts review the scientific rationale for combining BRAF, MEK and EGFR inhibition in BRAF-mutated mCRC; a strategy tested in such settings as the ANCHOR and BEACON trials.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME